Publicaciones (93) Publicaciones de JOSE FERNANDO MARIN DIEZ

2022

  1. Bilateral follicular variant of papillary thyroid cancer with different RAS mutations detected with next-generation sequencing: Report of an unusual case and literature review

    Diagnostic Cytopathology, Vol. 50, Núm. 10, pp. E275-E279

  2. The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS)

    Calcified Tissue International, Vol. 110, Núm. 1, pp. 74-86

2021

  1. Coexistence of dyschondrosteosis associated to SHOX deficiency, pseudohypoparathyroidism 1B, and chronic autoimmune thyroiditis: A case report

    Journal of Pediatric Endocrinology and Metabolism, Vol. 34, Núm. 4, pp. 531-534

  2. Teriparatide

    Osteoporotic Fracture and Systemic Skeletal Disorders: Mechanism, Assessment, and Treatment (Springer Nature), pp. 339-359

  3. The impact of repeat fine-needle aspiration in thyroid nodules categorized as atypia of undetermined significance or follicular lesion of undetermined significance: A single center experience

    Diagnostic Cytopathology, Vol. 49, Núm. 3, pp. 412-417

  4. Treatment of Chronic Nonunion of a Sternal Fracture With Teriparatide

    Annals of Thoracic Surgery, Vol. 111, Núm. 1, pp. e41-e42

  5. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained

    Journal of Bone and Mineral Research, Vol. 36, Núm. 2, pp. 236-243

2020

  1. Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial

    Calcified Tissue International, Vol. 106, Núm. 6, pp. 646-654

  2. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial

    Osteoporosis International, Vol. 31, Núm. 10, pp. 1935-1942

  3. Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use"

    Journal of Clinical Endocrinology and Metabolism

  4. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

    Bone, Vol. 130

  5. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials

    The Lancet Diabetes and Endocrinology, Vol. 8, Núm. 8, pp. 672-682

2019

  1. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

    Journal of Bone and Mineral Research, Vol. 34, Núm. 4, pp. 632-642

  2. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis

    Bone, Vol. 120, pp. 1-8

  3. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies

    Calcified Tissue International, Vol. 104, Núm. 2, pp. 193-200

  4. Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

    Journal of Bone and Mineral Research

  5. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

    Archives of Osteoporosis, Vol. 14, Núm. 1

  6. Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS)

    Current Medical Research and Opinion, Vol. 35, Núm. 6, pp. 1041-1049

2018

  1. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

    Journal of Bone and Mineral Research, Vol. 33, Núm. 5, pp. 783-794

  2. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

    Calcified Tissue International, Vol. 103, Núm. 4, pp. 359-371